Verona Pharma plc (VRNA)
NASDAQ: VRNA · Real-Time Price · USD
106.82
+0.11 (0.10%)
At close: Oct 1, 2025, 4:00 PM EDT
106.84
+0.02 (0.02%)
After-hours: Oct 1, 2025, 4:15 PM EDT
Verona Pharma Stock Forecast
Stock Price Forecast
The 10 analysts that cover Verona Pharma stock have a consensus rating of "Buy" and an average price target of $114.1, which forecasts a 6.82% increase in the stock price over the next year. The lowest target is $57 and the highest is $170.
Price Target: $114.1 (+6.82%)
Analyst Consensus: Buy
* Price targets were last updated on Jul 14, 2025.
Analyst Ratings
The average analyst rating for Verona Pharma stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Apr '25 | May '25 | Jun '25 | Jul '25 | Aug '25 | Sep '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 5 | 3 | 3 | 3 |
| Buy | 1 | 1 | 3 | 3 | 3 | 3 |
| Hold | 0 | 0 | 0 | 5 | 5 | 5 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 5 | 8 | 11 | 11 | 11 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy → Hold Downgrades $90 → $107 | Strong Buy → Hold | Downgrades | $90 → $107 | +0.17% | Jul 14, 2025 |
| Wells Fargo | Wells Fargo | Buy → Hold Downgrades $138 → $107 | Buy → Hold | Downgrades | $138 → $107 | +0.17% | Jul 10, 2025 |
| BTIG | BTIG | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | Jul 10, 2025 |
| Jefferies | Jefferies | Strong Buy → Hold Downgrades $140 → $107 | Strong Buy → Hold | Downgrades | $140 → $107 | +0.17% | Jul 9, 2025 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy → Hold Downgrades $107 | Strong Buy → Hold | Downgrades | $107 | +0.17% | Jul 9, 2025 |
Financial Forecast
Revenue This Year
427.00M
from 42.28M
Increased by 909.96%
Revenue Next Year
753.54M
from 427.00M
Increased by 76.47%
EPS This Year
0.52
from -2.16
EPS Next Year
2.20
from 0.52
Increased by 325.94%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 514.5M | 943.3M | |||
| Avg | 427.0M | 753.5M | |||
| Low | 361.7M | 545.6M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 1,116.9% | 120.9% | |||
| Avg | 910.0% | 76.5% | |||
| Low | 755.5% | 27.8% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 1.56 | 4.46 | |||
| Avg | 0.52 | 2.20 | |||
| Low | -0.11 | 0.37 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | 762.1% | |||
| Avg | - | 325.9% | |||
| Low | - | -28.1% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.